You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Producing Novel Biosynthetic Therapeutics from Extreme Microbiomes

    SBC: iXpressGenes, Inc.            Topic: CBD152004

    Environmental DNA from three extreme samples will be isolated, cloned into a fosmid library (5760 clones) for sequencing. The sequencing datawill cover ~ 240 Megabases and will be assembled into contigs long enough (~ 40 Kilobases) to represent potential biosynthetic gene clusters(BGCs). This data will be compared to BGC databases looking for homology to antibiotic targets of DoD interest and with ...

    SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  2. Protective Mask Sizing App

    SBC: CFD RESEARCH CORPORATION            Topic: CBD161005

    Typical procedures for respirator masks sizing and protective fit test are time-consuming and user intensive, requiring taking anthropometric measurements of the wearer, sampling the wearers breathing zone and the use of specialized tools and equipment. The proposed software app aims to quickly, accurately and automatically perform respirator mask sizing and predict protective fit using only 2D im ...

    SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  3. Single domain antibodies as medical countermeasures for viral induced encephalitis

    SBC: ABZYME THERAPEUTICS LLC            Topic: CBD161004

    Alphavirus infection, which may cause encephalitis and death, are recognized as potential biological warfare agents. There are no approved medical countermeasures against diseases caused by Alphaviruses. In this project, thermostable single domain antibodies capable of crossing the blood brain barrier (BBB) and neutralizing encephalitic viruses will be developed using Abzymes proprietary in vivo S ...

    SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  4. Human monoclonal antibodies as countermeasures for T-2 mycotoxin

    SBC: ABZYME THERAPEUTICS LLC            Topic: CBD152003

    Mycotoxins are fungal toxins to which exposure frequently results in incapacitation or even in death. Natural outbreaks of mycotoxin poisoningare common worldwide. Due to its physical-chemical properties, high toxicity and relative ease to produce, mycotoxin T-2 is classified as apotential biological warfare agent. Currently there are no FDA approved medical countermeasures available for T-2 mycot ...

    SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  5. Exploiting Natural Products-Based Therapeutics for Aflatoxin Mitigation

    SBC: CFD RESEARCH CORPORATION            Topic: CBD152003

    Aflatoxins are a paradigm among fungal produced mycotoxins that are present in food supplies and are strongly associated with increased risk forthe development of hepatocellular carcinoma. Currently, there are no known countermeasures that can selectively mitigate aflatoxin toxicity andthe available options are only symptomatic treatments. To meet this challenge, we propose to harness the microbio ...

    SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government